Study at a glance
Why can vitamin D activation differ between people?
The amount of vitamin D available for activation, how well the kidneys work, hormone signals and the enzymes involved can differ. These factors affect how the same basic process works.
Can tissues in one person activate vitamin D differently?
Yes. Some cells can make active vitamin D locally. Their ability to do this depends on the cell type and its condition. They do not all behave like the kidneys.
Does a blood vitamin D result show what every tissue is doing?
No. It provides useful information about a form carried in the blood, but it does not directly measure activation and breakdown inside each tissue.
Can variation in activation tell me which dose I need?
No. Understanding how a process might work is different from establishing what one person needs. The experiments discussed here do not provide a personalised supplement plan.
Read the full article below ↓Vitamin D activation follows a recognisable metabolic pathway, but that does not mean the pathway operates identically in every person, tissue or physiological circumstance. Vitamin D3 must first be converted to 25-hydroxyvitamin D [25(OH)D], and 25(OH)D can then be converted to the active hormone 1,25-dihydroxyvitamin D [1,25(OH)2D]. Yet the availability of precursor, the regulation of renal activation, the activity of metabolic enzymes and the capacity for local activation outside the kidney can all vary.
This variability matters because vitamin D physiology is sometimes interpreted as though a single measurement or a single step in the pathway describes the entire system. It does not. Circulating vitamin D metabolites, endocrine regulation and local tissue metabolism represent connected but distinct aspects of vitamin D biology.
For the underlying pathway, see Vitamin D Activation.
The same pathway can operate under different physiological conditions
The basic activation sequence provides the biochemical framework: vitamin D3 undergoes 25-hydroxylation, producing 25(OH)D, and CYP27B1 can subsequently convert 25(OH)D to active 1,25(OH)2D. That framework is shared across vitamin D physiology, but the conditions surrounding each stage are not fixed.
The amount of substrate available for metabolism can differ. The activity and expression of enzymes involved in activation and degradation can differ. Endocrine signals can stimulate or suppress renal activation. Different tissues can also possess different capacities to metabolise the 25(OH)D available to them.
As a result, knowing the pathway does not mean that the metabolic output can be predicted from one input alone. Vitamin D activation occurs within a regulated biological system rather than through an uncontrolled sequence of conversions.
Precursor availability is only one part of the picture
25(OH)D occupies an important position in vitamin D physiology because it provides the major circulating precursor from which active vitamin D can be produced. Differences in precursor availability can therefore affect the substrate presented to tissues capable of further metabolism.
But precursor availability should not be confused with active-hormone production. Having more or less 25(OH)D available does not mean that every tissue will convert it into 1,25(OH)2D at the same rate. The metabolic fate of that precursor depends on the enzymes, regulatory signals and cellular conditions operating where the precursor is encountered.
This distinction is particularly important when moving from a description of circulating vitamin D status to a description of what may be happening within a specific tissue. A circulating measurement and a local metabolic process answer different biological questions.
Renal activation responds to the body’s wider mineral physiology
The kidney is an important regulated site of active-vitamin-D production. Renal CYP27B1 does not simply convert whatever 25(OH)D reaches it at a constant rate. Its activity sits within an endocrine network involving parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), active vitamin D itself and the wider physiology of calcium and phosphate balance.
This creates an important source of physiological variability. Changes elsewhere in the mineral-homeostasis system can alter the hormonal environment in which renal vitamin D activation occurs. Conversely, changes in active-vitamin-D production can feed back into that same system.
Calcium, phosphate, PTH and FGF23 should not be treated as interchangeable direct regulators. PTH and FGF23 provide important endocrine signals affecting renal CYP27B1 regulation, while calcium and phosphate participate in the broader homeostatic system within which those hormonal responses operate.
For the enzyme framework involved in activation and degradation, see Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).
Different tissues do not necessarily handle vitamin D in the same way
Vitamin D metabolism is distributed across different biological locations. The liver and kidney occupy major positions in the conventional activation pathway, but selected cells outside the kidney can also express metabolic machinery capable of converting 25(OH)D into active 1,25(OH)2D.
This means that the presence of the same circulating precursor does not guarantee the same metabolic response everywhere in the body. Different tissues can differ in enzyme expression, cellular environment and metabolic purpose.
Extra-renal activation is especially important to this distinction. Local production of active vitamin D within a peripheral cell does not necessarily have the same physiological role as renal production contributing to the endocrine system. The metabolite may be chemically the same while the biological context in which it is produced is different.
For the broader comparison of vitamin D metabolism between tissues, see Tissue-Specific Vitamin D Metabolism.
Cellular state can change vitamin D metabolism
Variation can occur not only between organs but also between different functional states of the same broad cell type. Cells change their behaviour in response to their biological environment, and vitamin D-metabolising machinery can form part of that changing phenotype.
Experimental work in human macrophages provides a useful example. Macrophages in different functional states did not process supplied 25(OH)D identically. Some generated substantially more active 1,25(OH)2D than others, demonstrating that local activation capacity can depend on cellular phenotype.
This should not be generalised into the claim that every change in cellular state produces the same alteration in vitamin D metabolism. Instead, it demonstrates a broader physiological principle: metabolic capacity can depend on the biological condition of the cell performing the metabolism.
For the cellular framework underlying these processes, see Vitamin D Metabolism at the Cellular Level.
Activation and inactivation occur together
Another source of variability is that vitamin D metabolism is not governed by activation alone. CYP27B1 contributes to formation of active 1,25(OH)2D, while CYP24A1 participates in metabolic pathways that limit or redirect the activity of vitamin D metabolites.
The biological outcome therefore depends partly on the balance between production and further metabolism. Two cellular environments presented with similar substrate availability could behave differently if the relative activity of their activation and inactivation pathways differed.
This is why the presence of precursor, the expression of one enzyme or the concentration of one metabolite cannot by itself describe the complete metabolic state of a tissue.
Circulating measurements and local tissue biology answer different questions
Blood measurements are valuable because they provide information about metabolites circulating through the body. But a blood concentration is not a direct measurement of every metabolic process occurring within every tissue.
25(OH)D can provide information about the circulating precursor pool, while circulating 1,25(OH)2D reflects another part of vitamin D physiology. Neither measurement directly reveals the rate at which a particular peripheral cell is producing, using or further metabolising vitamin D compounds within its local environment.
The distinction is not that circulating measurements are uninformative. It is that systemic measurements and local cellular metabolism operate at different biological scales. Interpreting one as though it completely describes the other would erase an important layer of vitamin D physiology.
Why individual variation cannot be reduced to one factor
Differences in vitamin D physiology between people cannot automatically be attributed to a single stage of activation. Variation may occur before activation through differences in precursor availability, during renal activation through endocrine regulation, within peripheral tissues through local metabolic capacity, or through pathways involved in further metabolism and inactivation.
These processes can also interact. A change in one part of the system may provoke compensatory responses elsewhere. Mineral homeostasis provides a clear example: changes involving vitamin D metabolism, PTH, FGF23, calcium and phosphate can produce feedback responses that make the overall physiological result less straightforward than a simple linear pathway would suggest.
Individual variation therefore does not imply that the underlying activation pathway is different in every person. It means that a shared biochemical framework operates within biological systems whose inputs, regulatory signals and tissue conditions can differ.
What this variability does not tell us
Recognising variability in vitamin D activation does not establish an individual’s vitamin D requirement, optimal blood concentration or supplementation strategy. Mechanistic evidence explaining how activation can vary is different from clinical evidence establishing what a particular person should consume or what treatment they may require.
Nor does evidence of extra-renal activation mean that every tissue makes physiologically important quantities of active vitamin D or that local production necessarily produces measurable changes in circulating 1,25(OH)2D.
Similarly, evidence that renal activation is hormonally regulated should not be interpreted as showing that every difference in circulating vitamin D metabolites results from altered kidney function. Vitamin D status and metabolism reflect multiple biological processes, and the contribution of any one mechanism depends on the circumstances being examined.
Putting real-world variability into context
The most useful interpretation is therefore neither that vitamin D activation is a fixed two-step conveyor belt nor that the pathway is so variable that its basic structure loses meaning. Both ideas miss part of the physiology.
The biochemical pathway provides the common framework. Vitamin D3 is converted to 25(OH)D, and 25(OH)D can subsequently be converted to active 1,25(OH)2D. Around that framework sit several layers of regulation: substrate availability, endocrine control, tissue-specific enzyme activity, cellular state and metabolic inactivation.
Those layers help explain why the same underlying pathway can operate differently across biological circumstances without requiring a different biochemical model for every person or tissue.
Understanding vitamin D activation therefore requires both levels of explanation: the core metabolic sequence and the physiological context that determines how that sequence is regulated and expressed.
Return to the parent physiology page: Vitamin D Activation.
Related reading
The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →Extra-Renal Vitamin D Activation: Full Evidence Review
Evidence review of human macrophage research directly demonstrating extra-renal conversion of 25(OH)D to active 1,25(OH)2D and variation by cell state.
Read more →Extra-Renal Vitamin D Activation: Study Summary
Concise summary of human macrophage research showing direct conversion of 25(OH)D to active vitamin D and differences between macrophage phenotypes.
Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Renal Vitamin D Activation: Full Evidence Review
Evidence review examining how PTH, FGF23 and active vitamin D regulate renal Cyp27b1 and connect vitamin D activation with mineral homeostasis.
Read more →Renal Vitamin D Activation: Study Summary
Study summary explaining how PTH, FGF23 and active vitamin D regulate renal Cyp27b1 and influence vitamin D and mineral homeostasis.
Read more →25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Full Study
Explore why 25(OH)D reflects vitamin D status while 1,25(OH)₂D is a tightly regulated active hormone, including PTH, FGF23 and renal control.
Read more →Calcitriol affects hCG gene transcription in cultured human syncytiotrophoblasts
In pregnancy, maternal serum concentrations of calcitriol significantly rise as a result of increased renal and placental contribution in order to assure calcium supply for the developing fetus.
Original paper ↗Read more →Calcitriol induces cell senescence of kidney cancer through JMJD3 mediated histone demethylation
In this study, the biological effect and epigenetic regulation of calcitriol on kidney cancer cells were investigated.
Original paper ↗Read more →Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD).
Original paper ↗Read more →Low-dose oral cholecalciferol is associated with higher numbers of Helios+ and total Tregs than oral calcitriol in renal allograft recipients: an observational study
We evaluated whether there was a difference in the absolute numbers of Helios+, Helios−, CTLA-4+, IFNg+, and total Tregs among the patient groups.
Original paper ↗Read more →Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial
This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD.
Original paper ↗Read more →Protective effect of calcitriol on rhabdomyolysis-induced acute kidney injury in rats
This study evaluated the effect of calcitriol administration in AKI induced by rhabdomyolysis and its relationship with oxidative damage and inflammatory process.
Original paper ↗Read more →Spatial detection and consequences of nonrenal calcitriol production as assessed by targeted mass spectrometry imaging
Here, utilizing on-tissue chemical derivatization and matrix assisted laser desorption ionization-mass spectrometry imaging (MALDI-MSI), we investigated the distribution of 1,25(OH)2D3 and 25(OH)D3 in the kidney, liver, spleen, and thymus.
Original paper ↗Read more →L-shaped association of serum 25-hydroxyvitamin D with all-cause and cardiovascular mortality in older people with chronic kidney disease: results from the NHANES database prospective cohort study
We identified 3230 CKD participants aged ≥ 60 years from the National Health and Nutrition Examination Survey (2001 to 2018).
Original paper ↗Read more →Assessment of Serum 25-Hydroxyvitamin D and Its Association in Type 2 Diabetes Mellitus Elderly Patients with Kidney Disease: A Retrospective Cross Sectional Study
The overall aim of this study is to determine the prevalence of vitamin D deficiency and its association with diabetic nephropathy in elderly patients with type 2 diabetes mellitus.
Original paper ↗Read more →Association between serum 25-hydroxyvitamin D levels and carotid atherosclerosis in chronic kidney disease patients
Therefore, in this study we have aimed to determine the association between serum 25-hydroxyvitamin D levels and carotid atherosclerosis in the CKD population.
Original paper ↗Read more →Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Concentrations and Postoperative Infections in Cardiac Surgical Patients: The CALCITOP-Study
In 3,340 consecutive cardiac surgical patients, we investigated the association of circulating 25-hydroxyvitamin D (25OHD; indicator of nutritional vitamin D status) and 1,25-dihydroxyvitamin D (1,25[OH]2D; active vitamin D hormone) with nosocomicial infections.
Original paper ↗Read more →Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort
This study investigated whether the renal function category and prior treatment history modified the association between baseline 25OHD and romosozumab BMD response.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels in Breast Cancer Risk in Mali: A Case-Control Study
The aim of the current study was to determine the association between metabolites circulating in the blood, 25(OH)D and 1,25(OH)2D, and vitamin D levels with the risk of breast cancer in Malian women.
Original paper ↗Read more →Serum free 25(OH)D concentrations and cardiovascular disease, heart failure, kidney function decline, and fracture: the health, aging, and body composition study
We evaluated the relationship of free vitamin D with incident cardiovascular disease (CVD), heart failure (HF), kidney function decline (KFD) and fracture, among 786 participants in the Health Aging and body composition study.
Original paper ↗Read more →